Skip Navigation

Zolgensma Infusion For Spinal Muscular Atrophy, Inpatient

Zolgensma is a one-time genetic therapy for patients under two years old diagnosed with Spinal Muscular Atrophy (SMA), a condition in which the Survival Motor Neuron 1 (SMN1) gene is missing or functioning poorly. Zolgensma delivers a new gene to produce survival motor neuron protein and preserve motor neuron cells throughout the body, supporting and sustaining muscle function and stopping the progression of SMA.

1 Result(s)
4650 Sunset Blvd
2252 Miles

The Bundled Rate plus Outlier Per Diems includes:

1. Those comprehensive facility services, supplies, and equipment necessary to perform the Bundled Procedure and rendered by PROVIDER 2. Those professional services necessary to perform the Bundled Procedure and rendered by a Physician 3. The treatment of any complication or concurrent related illness associated with or resulting from the performance of the Bundled Procedure The Bundled Rate period begins on the day of the prep regime for the scheduled Accarent Procedure and covers up to 3 inpatient days in the hospital. Should the length of stay exceed 3 inpatient days, then per diem outlier payments will be applicable for each subsequent inpatient day. Covered outpatient follow-up services related to the bundled procedure beginning on the day of infusion through 60 calendar days are included in the bundled price.


Complications or co-morbidities unrelated to the procedure requiring inpatient admission. Patients older than 24 months at the time of treatment.


Candidacy for the bundled procedure will be determined by the Provider.